About the Company

Home » About DUSA

Brief Overview:

DUSA Pharmaceuticals, Inc.® (NASDAQGM: DUSA) is a fully integrated specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform used in conjunction with it’s proprietary light source, the BLU-U® Blue Light Photodynamic Therapy Illuminator. Levulan Kerastick® (aminolevulinic acid HCl) for Topical Solution, 20% in combination with the BLU-U is approved by the U.S. Food and Drug Administration for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. Actinic Keratosis is the most frequently diagnosed skin disease by U.S. dermatologists. PDT is a two part process in which the target cells are made extremely sensitive to light and then exposed to blue light, which destroys the cells. DUSA® also markets other dermatology products, including ClindaReach® (clindamycin phosphate topical solution USP, 1%) Pledgets, an acne treatment for hard-to-reach areas and BLU-U, which as a stand alone device, uses light to treat mild to moderate inflammatory acne. DUSA is based in Wilmington, MA. 

Key Figures:

  • DUSA has 86 employees, of which 46 are in Sales and Marketing
  • U.S. dermatologists utilizing DUSA products have grown to more than 2,300
  • Full year 2009 financial results: total revenues $29.8M, domestic Levulan revenues up 23%, non-GAAP net loss improved 74% to ($1.0M)
  • Five year Levulan revenue CAGR of 35%
  • September 2010 trailing twelve months total revenues $34.2M
  • Company cash flow positive and/or profitable over last 4 quarters

 Portfolio of Products: 

  • Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20%
  • BLU-U Blue Light Photodynamic Therapy Illuminator
  • ClindaReach (Clindamycin Phosphate Topical Solution USP, 1%) Pledgets

Company Milestones:

1992

  • DUSA Pharmaceuticals, Inc. becomes a public company listed on the NASDAQ exchange  

2000   

  • Levulan in combination with the BLU-U receives approval from the U.S. FDA for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp
  • Levulan Kerastick and the BLU-U are launched in the U.S. by Berlex Laboratories, Inc., a subsidiary of Schering AG

2003                

  • BLU-U receives clearance from the FDA for the light alone treatment of mild to moderate inflammatory acne vulgaris
  • DUSA terminates Worldwide Marketing Agreement with Schering AG and opts to build out its own direct sales force
  • DUSA U.S. sales force begins with 6 representatives 

2005                

  • Robert Doman hired as President and COO
  • U.S. sales force expands to 24
  • DUSA receives Hatch-Waxman patent term extension for Levulan through September, 2013

2006 

  • DUSA signs a Licensing Agreement on Levulan with Stiefel Laboratories for Latin America
  • DUSA acquires Sirius Laboratories
  • U.S. sales force increased to 37

2007

  • Robert Doman appointed CEO
  • DUSA signs a Licensing Agreement with Daewoong Pharmaceutical for the Asian markets
  • Levulan launched in Korea

2008 

  • DUSA named to Deloitte Technology Fast 500 as one of the fastest growing companies in North America
  • U.S. sales force increased to 41 

2009 

  • Levulan Kerastick cumulative sales volume surpasses one million units
  • DUSA named to Deloitte Technology Fast 500 for second consecutive year
  • Company reaches quarterly profitability and generates $1.6M in positive cash flow in Q4

2010

  • September year-to-date financials; total revenues $25.4M, domestic Levulan revenues $21.8M (+27%), Levulan gross margin 87%, non-GAAP net income $1.2M, positive cash flow $0.3M
  • USPTO issued new patent with claims that cover DUSA’s blue light technology in conjunction with its proprietary Levulan Kerastick through June 2019
  • DUSA terminates its Agreement with Stiefel Laboratories after their acquisition by Glaxo-Smith-Kline (GSK)
  • DUSA named to Deloitte Technology Fast 500 for third consecutive year

2011

  • Sales force expanded from 36 territories to 40 and 4 region managers to 5
  • DUSA added to the U.S. broad-market Russell 3000 Index
  • First half domestic Levulan Kerastick revenue up 28%. Non-GAAP Net Income of $4.2M matches total for all of 2010. Positive cash flow of $4.5M exceeds full year 2010 cash flow by more than 50%.

 

 

  

WEB 1385 Rev F